

Elihu Estey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2868019/publications.pdf>

Version: 2024-02-01

168
papers

20,212
citations

41344

49
h-index

10734

138
g-index

176
all docs

176
docs citations

176
times ranked

14239
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	1.4	4,375
2	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	1.4	2,963
3	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	1.6	2,425
4	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Cancer</i> , 2006, 106, 1090-1098.	4.1	550
5	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , 2014, 15, 986-996.	10.7	549
6	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005, 104, 1442-1452.	4.1	429
7	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	1.4	393
8	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006, 107, 3469-3473.	1.4	371
9	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	1.6	361
10	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. <i>Journal of Clinical Oncology</i> , 2009, 27, 504-510.	1.6	355
11	Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1190-1197.	1.6	351
12	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016, 34, 329-336.	1.6	347
13	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013, 122, 1813-1821.	1.4	325
14	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. <i>Journal of Clinical Oncology</i> , 2011, 29, 4417-4424.	1.6	287
15	Acute myeloid leukemia: 2019 update on risk-stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 1267-1291.	4.1	283
16	Acute myeloid leukaemia. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16010.	30.5	277
17	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012, 119, 6198-6208.	1.4	273
18	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). <i>Blood</i> , 2007, 109, 1395-1400.	1.4	249

#	ARTICLE	IF	CITATIONS
19	Acute myeloid leukemia: 2013 update on risk stratification and management. American Journal of Hematology, 2013, 88, 317-327.	4.1	234
20	Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 1258-1264.	1.6	223
21	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
22	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 889-903.	10.7	205
23	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood, 2009, 113, 28-36.	1.4	192
24	Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Journal of Clinical Oncology, 2010, 28, 1766-1771.	1.6	187
25	Experience with gemtuzumab ozogamycin (âœmylotargâœ) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood, 2002, 99, 4222-4224.	1.4	173
26	Use of arsenic trioxide (As ₂ O ₃) in the treatment of patients with acute promyelocytic leukemia. Cancer, 2003, 97, 2218-2224.	4.1	169
27	The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Reviews, 2014, 28, 143-153.	5.7	145
28	Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood, 2002, 99, 4343-4349.	1.4	141
29	Acute myeloid leukemia: 2014 Update on risk stratification and management. American Journal of Hematology, 2014, 89, 1063-1081.	4.1	131
30	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 89-99.	4.1	127
31	Development and Validation of a Novel Acute Myeloid LeukemiaâœComposite Model to Estimate Risks of Mortality. JAMA Oncology, 2017, 3, 1675.	7.1	125
32	Prognostic Significance of <i>NPM1</i> Mutations in the Absence of <i>FLT3</i> âœInternal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report. Journal of Clinical Oncology, 2015, 33, 1157-1164.	1.6	113
33	New designs for phase 2 clinical trials. Blood, 2003, 102, 442-448.	1.4	107
34	Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood, 2011, 118, 1490-1494.	1.4	100
35	Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood, 2000, 95, 72-77.	1.4	97
36	Gemtuzumab Ozogamicin: Time to Resurrect?. Journal of Clinical Oncology, 2012, 30, 3921-3923.	1.6	95

#	ARTICLE	IF	CITATIONS
37	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 927-934.	3.5	93
38	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 673-673.	1.4	90
39	Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 1722-1727.	1.6	86
40	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. <i>Blood Reviews</i> , 2017, 31, 185-192.	5.7	83
41	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2022, 139, 323-332.	1.4	80
42	Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work. <i>Blood</i> , 1997, 90, 4719-4724.	1.4	78
43	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	1.6	77
44	Acute myeloid leukemia: 2021 update on risk stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 1368-1398.	4.1	74
45	Current challenges in clinical development of targeted therapies: the case of acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2461-2466.	1.4	71
46	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , 2010, 116, 2420-2428.	1.4	70
47	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients \geq 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 48-48.	1.4	64
48	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 1311.	3.0	55
49	Using short-term response information to facilitate adaptive randomization for survival clinical trials. <i>Statistics in Medicine</i> , 2009, 28, 1680-1689.	1.6	54
50	Time to repeal and replace response criteria for acute myeloid leukemia?. <i>Blood Reviews</i> , 2018, 32, 416-425.	5.7	51
51	Acute myeloid leukemia: 2016 Update on risk stratification and management. <i>American Journal of Hematology</i> , 2016, 91, 824-846.	4.1	49
52	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
53	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. <i>Leukemia</i> , 2020, 34, 671-681.	7.2	46
54	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2015, 1, 1120.	7.1	43

#	ARTICLE	IF	CITATIONS
55	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 4050-4050.	1.4	43
56	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, 3883-3888.	1.6	42
57	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1263-1265.	3.5	40
58	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018, 32, 2352-2362.	7.2	39
59	Accounting for patient heterogeneity in phase II clinical trials. <i>Statistics in Medicine</i> , 2008, 27, 2802-2815.	1.6	38
60	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 571-7.	0.3	33
61	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 21-33.	2.5	31
62	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 421-432.	3.8	31
63	Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 546-551.	2.0	30
64	AML in older patients: Are we making progress?. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 529-536.	1.7	29
65	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1615-1620.	2.0	29
66	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013, 122, 61-61.	1.4	29
67	Relapse and death during first remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 633-634.	3.5	26
68	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. <i>Blood Reviews</i> , 2020, 44, 100679.	5.7	26
69	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). <i>Journal of Drug Assessment</i> , 2018, 7, 51-53.	2.2	25
70	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1226-1233.	1.3	24
71	Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. <i>Current Medical Research and Opinion</i> , 2018, 34, 2031-2039.	1.9	22
72	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 611-616.	5.2	21

#	ARTICLE	IF	CITATIONS
73	Treatment of AML: resurrection for gemtuzumab ozogamicin?. <i>Lancet, The</i> , 2012, 379, 1468-1469.	13.7	20
74	Why Is Progress in Acute Myeloid Leukemia So Slow?. <i>Seminars in Hematology</i> , 2015, 52, 243-248.	3.4	20
75	Acute Myeloid Leukemia "Many Diseases, Many Treatments. <i>New England Journal of Medicine</i> , 2016, 375, 2094-2095.	27.0	20
76	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Haematologica</i> , 2018, 103, e106-e109.	3.5	19
77	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 3239-3245.	5.2	19
78	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	1.4	18
79	New Drugs in Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 439-448.	2.2	17
80	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e97-e98.	3.5	16
81	High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 474-480.	2.5	15
82	Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 141, 104-105.	1.7	15
83	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. <i>JAMA Oncology</i> , 2019, 5, 1062.	7.1	14
84	Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. <i>Leukemia Research</i> , 2020, 89, 106298.	0.8	14
85	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function. <i>Cell Stem Cell</i> , 2022, 29, 577-592.e8.	11.1	13
86	Reply to D. Przepiora et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3676-3677.	1.6	12
87	New drugs in AML: uses and abuses. <i>Leukemia</i> , 2018, 32, 1479-1481.	7.2	12
88	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 395-400.e1.	0.4	11
89	Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3121-3130.	4.1	11
90	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , 2020, 34, 635-639.	7.2	11

#	ARTICLE	IF	CITATIONS
91	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013, 122, 356-356.	1.4	11
92	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015, 100, e409-e411.	3.5	10
93	Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 324-328.	1.7	9
94	Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. <i>Leukemia</i> , 2019, 33, 371-378.	7.2	9
95	The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2022, 196, 329-335.	2.5	9
96	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019, 33, 554-558.	7.2	8
97	Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 1411-1417.	4.1	8
98	New study-designs to address the clinical complexity of acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 567-569.	7.2	7
99	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1023-1029.	1.3	7
100	New treatments for acute myeloid leukemia: how much has changed?. <i>Leukemia</i> , 2021, 35, 45-46.	7.2	7
101	Management of persistent AML at day 14. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 235-240.	1.7	6
102	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
103	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013, 122, 3924-3924.	1.4	6
104	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. <i>Blood</i> , 2016, 128, 1613-1613.	1.4	6
105	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7021-7021.	1.6	6
106	Emerging treatments in acute myeloid leukemia: current standards and unmet challenges. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 632-642.	0.3	6
107	Intensity of conditioning for allogeneic haemopoetic cell transplantation. <i>Lancet Oncology</i> , The, 2012, 13, 966-968.	10.7	5
108	The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. <i>Blood</i> , 2013, 122, 293-294.	1.4	5

#	ARTICLE	IF	CITATIONS
109	Primacy of Resistance Rather Than Toxicity in Determining Outcome of Therapy for AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S56-S58.	0.4	5
110	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. <i>Leukemia Research</i> , 2014, 38, 258-262.	0.8	5
111	Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. <i>Blood</i> , 2013, 122, 3925-3925.	1.4	5
112	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. <i>Haematologica</i> , 2021, 106, 2114-2120.	3.5	4
113	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 234-238.	1.3	4
114	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 1364-1364.	1.4	4
115	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008, 112, 3253-3253.	1.4	4
116	Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?. <i>Journal of Clinical Oncology</i> , 2019, 37, 7031-7031.	1.6	4
117	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 27-36.	4.9	4
118	Response in acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 113-7.	0.3	4
119	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e254-e256.	3.5	3
120	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 782-784.	1.3	3
121	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2021, 62, 1532-1535.	1.3	3
122	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML. <i>Blood</i> , 2018, 132, 1513-1513.	1.4	3
123	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 260-260.	1.4	3
124	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. <i>Blood</i> , 2019, 134, 291-291.	1.4	3
125	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
126	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013, 2, 26-28.	0.4	2

#	ARTICLE	IF	CITATIONS
127	Allogeneic Transplantation for Acute Myelogenous Leukemia in CR1. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 205-206.	2.0	2
128	Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 3824-3824.	1.4	2
129	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. <i>Blood</i> , 2013, 122, 3936-3936.	1.4	2
130	Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay. <i>Blood</i> , 2013, 122, 483-483.	1.4	2
131	Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2021, , 1-10.	1.3	2
132	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013, 122, 64-64.	1.4	2
133	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing. <i>Leukemia Research</i> , 2022, 115, 106822.	0.8	2
134	What is the optimal induction strategy for older patients?. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 515-522.	1.7	1
135	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. <i>Leukemia and Lymphoma</i> , 2016, 57, 1205-1207.	1.3	1
136	“Looking beyond survival to define therapeutic value in acute myeloid leukemia”™. <i>Leukemia and Lymphoma</i> , 2019, 60, 1107-1109.	1.3	1
137	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , 2020, 34, 1169-1171.	7.2	1
138	Are phase III trials still important for FDA drug approval?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1287-1288.	1.3	1
139	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Blood</i> , 2019, 134, 4585-4585.	1.4	1
140	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. <i>Blood</i> , 2019, 134, 2729-2729.	1.4	1
141	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013, 122, 5002-5002.	1.4	1
142	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2569-2569.	1.4	1
143	Acute Myeloid Leukemia (AML). , 2012, , 1-36.		1
144	Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1305-1305.	1.4	1

#	ARTICLE	IF	CITATIONS
145	A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131).. Journal of Clinical Oncology, 2015, 33, TPS7096-TPS7096.	1.6	1
146	An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia. Blood, 2015, 126, 2602-2602.	1.4	1
147	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. Blood, 2020, 136, 12-13.	1.4	1
148	The times they are a-changin'. Blood, 2011, 117, 1774-1775.	1.4	0
149	Are immunoconjugates approaching â€œstandard of careâ€•in AML?. Best Practice and Research in Clinical Haematology, 2013, 26, 261-268.	1.7	0
150	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e633-e635.	0.4	0
151	Truth or consequences: under-reporting of post-accrual changes in clinical trial design. Leukemia and Lymphoma, 2020, 61, 2034-2035.	1.3	0
152	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of â€œAcute Myeloid Leukemia, Not Otherwise Specifiedâ€•in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. Blood, 2012, 120, 540-540.	1.4	0
153	Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study. Blood, 2012, 120, 4343-4343.	1.4	0
154	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. Blood, 2013, 122, 2932-2932.	1.4	0
155	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. Blood, 2015, 126, 5635-5635.	1.4	0
156	Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood, 2015, 126, 3776-3776.	1.4	0
157	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 1339-1339.	1.4	0
158	Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. Blood, 2015, 126, 688-688.	1.4	0
159	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. Blood, 2016, 128, 2792-2792.	1.4	0
160	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. Blood, 2018, 132, 3978-3978.	1.4	0
161	Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia. Blood, 2019, 134, 4674-4674.	1.4	0
162	More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels. Leukemia and Lymphoma, 2022, 63, 514-517.	1.3	0

#	ARTICLE	IF	CITATIONS
163	Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly. <i>Blood</i> , 2021, 138, 502-502.	1.4	0
164	Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015. <i>Blood</i> , 2021, 138, 4040-4040.	1.4	0
165	Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
166	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
167	Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies. <i>Leukemia</i> , 2022, , .	7.2	0
168	Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. <i>Leukemia</i> , 2022, , .	7.2	0